ALK and lung adenocarcinoma: The emergence of targeted therapy such as EGFR inhibitors and anaplastic lymphoma kinase (ALK) inhibitors have significantly changed the treatment strategy against lung adenocarcinoma AC, leading to marked improvements in patient survival.